A Phase 1 interventional study of AUY922 and BYL719 in Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 676 studies in Esophageal Neoplasms with a site in United States — 122 open to participants now, 172 under way, 2 of them phase 3. Esophageal Neoplasms · United States.
Among the 676 studies in Esophageal Neoplasms with a site in United States, this one is the 412th largest by enrollment of the 525 interventional ones that give a count, is one of 19 that started in 2012, is one of 167 in phase 1, and was the 308th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.
Browse Esophageal Neoplasms studies →122 of the 676 studies in Esophageal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+
Sutro Biopharma, Inc. · Sites in United States
Ages 18+
MacroGenics · Sites in United States
Ages 18+
Mark Bernard · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
676 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 234 · Phase 2 279 · Phase 3 19 · Phase 4 6
First in 1992; this study’s year is marked. 19 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 42 across the 525 interventional studies, 152 across the 112 observational. Of the 461 that completed or were terminated, 172 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
192 of 676 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 8 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
66 of the studies in Esophageal Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217704Phase 3SOFIEUsing 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | 2027-08-30 |
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
Add all 66 to your calendar (.ics) → With an account.
Among the 676 studies in Esophageal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is intended to investigate the safety of BYL719 and AUY922 in patients with advanced gastric cancer, and to determine the MTD and/or RDE of both drugs in combination. In addition, the preliminary efficacy of BYL719 in combination with AUY922, and the pharmacokinetics of both drugs will be assessed. Patients will be eligible for this study, if their tumors carry either a molecular alteration of PIK3CA, or an amplification of HER2.
The study includes a dose escalation part followed by a safety expansion phase.
Inclusion Criteria:
Recovery from all AEs of previous anti-cancer therapies, including surgery and radiotherapy, to baseline or to Grade ≤ 1, except for alopecia;Negative serum pregnancy (β hCG) test within 72 hrs before starting study treatment in all pre-menopausal women and women \< 12 months after the onset of menopause.
* Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.
Drug: AUY922 · Drug: BYL719
Incidence rate of Dose Limiting Toxicities.
To determine the maximum tolerated dose (MTD) and/or Recommended dose for expansion (RDE) and schedule of BYL719 and AUY922 when used as a combination in patients with advanced or metastatic gastric cancer carrying a molecular alteration of PIK3CA and/or an amplification of HER2. 1 cycle = 28days
Time frame: cycle 1
Frequency of adverse events (AEs)
To characterize the safety and tolerability of BYL719 and AUY922 in combination.
Time frame: duration of the study, an expected average of 24 months
Best Overall Response (BOR) as per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination from Treatment start to disease progression
Time frame: every 6 weeks
Plasma concentration versus time profiles of BYL719 as single agent an in combination with AUY922.
To determine the single dose PK of BYL719 single dose, and multiple doses PK of BYL719.
Time frame: 2 months
Overall response rate (ORR) as per RECIST version 1.1
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.
Time frame: an expected average of 12 months
Progression free survival (PFS) as per RECIST version 1.1
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.
Time frame: every 6 weeks
Overall survival (OS)
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.
Time frame: approximately 1 year
Overall survival rate at 6 months (OS6)
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.
Time frame: 6 months
Frequency and severity of serious adverse events (SAEs)
To characterize the safety and tolerability of BYL719 and AUY922 in combination.
Time frame: duration of the study, an expected average of 24 months
Plasma concentration versus time profile of AUY922 as single agent and in combination with BYL719
To determine the single dose and multiple dose pharmacokinetics of AUY922
Time frame: 2 months
Plasma concentration versus time profile of the AUY922 metabolite BJP762
To determine pharmacokinetics of BJP762 after single dose and multiple dose of AUY922
Time frame: 2 months
Severity of adverse events (AEs)
To characterize the safety and tolerability of BYL719 and AUY922 in combination.
Time frame: duration of the study, an expected average of 24 months
The record gives a start of Dec 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: auy922 · Alpelisib